JP2011518125A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011518125A5 JP2011518125A5 JP2011501904A JP2011501904A JP2011518125A5 JP 2011518125 A5 JP2011518125 A5 JP 2011518125A5 JP 2011501904 A JP2011501904 A JP 2011501904A JP 2011501904 A JP2011501904 A JP 2011501904A JP 2011518125 A5 JP2011518125 A5 JP 2011518125A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- fab fragment
- heavy chain
- light chain
- monoclonal antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3990708P | 2008-03-27 | 2008-03-27 | |
| US61/039,907 | 2008-03-27 | ||
| PCT/US2009/037349 WO2009120530A1 (en) | 2008-03-27 | 2009-03-17 | Glucagon receptor antagonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011518125A JP2011518125A (ja) | 2011-06-23 |
| JP2011518125A5 true JP2011518125A5 (enExample) | 2012-04-12 |
| JP5438095B2 JP5438095B2 (ja) | 2014-03-12 |
Family
ID=40794248
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011501904A Expired - Fee Related JP5438095B2 (ja) | 2008-03-27 | 2009-03-17 | グルカゴン受容体アンタゴニスト |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US7968686B2 (enExample) |
| EP (1) | EP2268670A1 (enExample) |
| JP (1) | JP5438095B2 (enExample) |
| KR (1) | KR101235934B1 (enExample) |
| CN (1) | CN101983208A (enExample) |
| AR (1) | AR070844A1 (enExample) |
| AU (1) | AU2009228866A1 (enExample) |
| BR (1) | BRPI0910118A2 (enExample) |
| CA (1) | CA2719761A1 (enExample) |
| CL (1) | CL2009000586A1 (enExample) |
| EA (1) | EA201071126A1 (enExample) |
| MX (1) | MX2010010517A (enExample) |
| PE (1) | PE20091674A1 (enExample) |
| TW (1) | TW201000126A (enExample) |
| WO (1) | WO2009120530A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013503626A (ja) * | 2009-09-08 | 2013-02-04 | ネオファーム シーオー．， エルティーディー． | グルカゴン受容体に対する抗体と、それらの使用 |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| US8771696B2 (en) | 2010-11-23 | 2014-07-08 | Regeneron Pharmaceuticals, Inc. | Method of reducing the severity of stress hyperglycemia with human antibodies to the glucagon receptor |
| JO3756B1 (ar) * | 2010-11-23 | 2021-01-31 | Regeneron Pharma | اجسام مضادة بشرية لمستقبلات الجلوكاجون |
| EP3252076B1 (en) | 2011-01-14 | 2019-09-04 | The Regents Of The University Of California | Diagnostic use of antibodies against ror-1 protein |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013059531A1 (en) * | 2011-10-20 | 2013-04-25 | Genentech, Inc. | Anti-gcgr antibodies and uses thereof |
| US9453073B2 (en) | 2011-12-02 | 2016-09-27 | Eli Lilly And Company | Anti-glucagon antibodies and uses thereof |
| WO2014181229A2 (en) * | 2013-05-07 | 2014-11-13 | Rinat Neuroscience Corp. | Anti-glucagon receptor antibodies and methods of use thereof |
| MX388503B (es) | 2014-06-08 | 2025-03-11 | Remd Biotherapeutics Inc | Uso de anticuerpos antagonistas del receptor de glucagon en el tratamiento de diabétes tipo 1. |
| KR102708864B1 (ko) | 2016-08-30 | 2024-09-25 | 리제너론 파마슈티칼스 인코포레이티드 | 글루카곤 수용체 신호전달을 간섭함에 의한 중증 인슐린 저항성의 치료 방법 |
| US20190248888A1 (en) | 2016-10-20 | 2019-08-15 | Regeneron Pharmaceuticals, Inc. | Methods of lowering blood glucose levels |
| PE20191404A1 (es) | 2017-01-27 | 2019-10-04 | Ngm Biopharmaceuticals Inc | Proteinas de union al receptor de glucagon y metodos para usarlas |
| JP7781519B2 (ja) | 2017-08-22 | 2025-12-08 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | グルカゴン受容体シグナル伝達に干渉することによって尿素サイクル異常症を治療する方法 |
| CN110357959B (zh) * | 2018-04-10 | 2023-02-28 | 鸿运华宁（杭州）生物医药有限公司 | Gcgr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用 |
| US10961315B2 (en) | 2018-07-27 | 2021-03-30 | Ngm Biopharmaceuticals, Inc. | Method of treating type I diabetes by administering a combination of a glucagon receptor antagonist and an anti-CD3 antibody |
| BR112021011595A2 (pt) | 2018-12-21 | 2021-11-30 | Jiangsu Hengrui Medicine Co | Proteína biespecífica |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5776725A (en) | 1992-08-28 | 1998-07-07 | Zymogenetics, Inc. | Recombinant production of glucagon receptors |
| ATE285472T1 (de) | 1992-08-28 | 2005-01-15 | Novo Nordisk As | Glucagonrezeptoren |
| US6909031B2 (en) | 2000-12-06 | 2005-06-21 | Deltagen, Inc. | Transgenic mice containing glucagon receptor gene disruptions |
| AR036711A1 (es) | 2001-10-05 | 2004-09-29 | Bayer Corp | Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico |
| US7399853B2 (en) | 2003-04-28 | 2008-07-15 | Isis Pharmaceuticals | Modulation of glucagon receptor expression |
| WO2006005469A2 (en) | 2004-07-15 | 2006-01-19 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with glucagon receptor (gcgr) |
| WO2008003641A1 (en) | 2006-07-04 | 2008-01-10 | Bracco Imaging S.P.A. | Device for localized thermal ablation of biological tissue, particularly tumoral tissues or the like |
| CL2007002668A1 (es) * | 2006-09-20 | 2008-05-09 | Amgen Inc | Proteina de union a antigeno que se une al receptor de glucagon humano; acido nucleico que la codifica; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir la diabetes tipo 2. |
-
2009
- 2009-03-12 CL CL2009000586A patent/CL2009000586A1/es unknown
- 2009-03-12 AR ARP090100889A patent/AR070844A1/es unknown
- 2009-03-12 PE PE2009000369A patent/PE20091674A1/es not_active Application Discontinuation
- 2009-03-13 TW TW098108296A patent/TW201000126A/zh unknown
- 2009-03-17 EP EP09726006A patent/EP2268670A1/en not_active Withdrawn
- 2009-03-17 CA CA2719761A patent/CA2719761A1/en not_active Abandoned
- 2009-03-17 BR BRPI0910118A patent/BRPI0910118A2/pt not_active IP Right Cessation
- 2009-03-17 CN CN2009801107130A patent/CN101983208A/zh active Pending
- 2009-03-17 WO PCT/US2009/037349 patent/WO2009120530A1/en not_active Ceased
- 2009-03-17 JP JP2011501904A patent/JP5438095B2/ja not_active Expired - Fee Related
- 2009-03-17 AU AU2009228866A patent/AU2009228866A1/en not_active Abandoned
- 2009-03-17 US US12/405,458 patent/US7968686B2/en not_active Expired - Fee Related
- 2009-03-17 EA EA201071126A patent/EA201071126A1/ru unknown
- 2009-03-17 MX MX2010010517A patent/MX2010010517A/es not_active Application Discontinuation
- 2009-03-17 KR KR1020107021297A patent/KR101235934B1/ko not_active Expired - Fee Related
-
2011
- 2011-05-16 US US13/108,073 patent/US20110212092A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011518125A5 (enExample) | ||
| JP2020079252A5 (enExample) | ||
| IL261585A (en) | Antigen-binding human proteins that bind beta-klotho, fgf receptors and their complexes | |
| JP2020500538A5 (enExample) | ||
| JP2012504955A5 (enExample) | ||
| JP2022061992A5 (enExample) | ||
| IL259940B2 (en) | Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists | |
| JP2009511480A5 (enExample) | ||
| JP2011517447A5 (enExample) | ||
| RU2588467C3 (ru) | Стабильные и растворимые антитела, ингибирующие vegf | |
| JP2019504032A5 (enExample) | ||
| JP2013538553A5 (enExample) | ||
| JP2018108081A5 (enExample) | ||
| JP2009225799A5 (enExample) | ||
| AR080698A1 (es) | Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e | |
| RU2017134495A (ru) | Антитела к альфа-рецептору собачьего интерлейкина-4 | |
| JP2018521638A5 (enExample) | ||
| JP2012504634A5 (enExample) | ||
| JP2011528902A5 (enExample) | ||
| JP2015522252A5 (enExample) | ||
| JP2010534478A5 (enExample) | ||
| JP2017514461A5 (enExample) | ||
| JP2010516229A5 (enExample) | ||
| FI3484915T3 (fi) | Uusia zikavirusepitooppeihin spesifisesti sitoutuvia vasta-aineita ja niiden käyttöjä | |
| JP2012513214A5 (enExample) |